ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 7, 2024—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announce that groundbreaking...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 25, 2024—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the...
The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making. ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 13,...
The Merlin Test (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October...
ROTTERDAM, (the Netherlands), SAN DIEGO (CA, USA), October 8, 2024 – SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announces...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), July 9, 2024: — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, proudly...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 30, 2024: — SkylineDx announces the presentation of groundbreaking data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Dr. Teresa Amaral,...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), April 5, 2024: — SkylineDx is pleased to announce two forthcoming scientific publications at the European Association for Dermato-Oncology congress, April 4-6, 2024. These publications...
ROTTERDAM (the Netherlands), SAN DIEGO (USA), March 24, 2022: today, SkylineDx announced that their Merlin Test for melanoma patients was independently validated in a Swedish (European) cohort, where it could reduce approximately a...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 20, 2024: – SkylineDx, an innovative molecular diagnostics company, proudly announces the launch of its new corporate website, a testament to the company’s commitment...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), March 8, 2024: — SkylineDx, an innovative molecular diagnostics company, announces the forthcoming presentation of an impactful poster by Dr. Yu from University Hospital Cleveland...
ROTTERDAM, the Netherlands, SAN DIEGO, CA, USA – January 9, 2024: SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 11, 2023: — SkylineDx, an innovative molecular diagnostics company, is thrilled to announce that a collaborative project for precision medicine, POINTILLISM 2.0, has been selected...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 8th 2023: – SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics is looking forward to the release of new data...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), December 5, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, is announcing a strategic commercial...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), November 6, 2023: — SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 31, 2023: SkylineDx an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, proudly announces the successful clinical...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), September 28, 2023: SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, announced that a new peer-reviewed...
